3.30
price up icon1.23%   0.04
 
loading

Lipocine Inc Aktie (LPCN) Neueste Nachrichten

pulisher
09:18 AM

What analysts say about Lipocine Inc. stockFree Daily Trading Room Entry - jammulinksnews.com

09:18 AM
pulisher
Jul 22, 2025

What drives Lipocine Inc. stock priceBreakthrough stock performance - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Lipocine Inc. Stock Analysis and ForecastSpectacular growth rates - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is Lipocine Inc. a good long term investmentRecord-setting profit potential - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 16, 2025

What makes Lipocine Inc. stock price move sharplyTrade With Low Risk Exposure - beatles.ru

Jul 16, 2025
pulisher
Jul 15, 2025

How Lipocine Inc. stock performs during market volatilitySmall Risk Large Return Trades - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Lipocine Inc. stock attracts strong analyst attentionStable Growth Stock Picks - Newser

Jul 15, 2025
pulisher
Jul 11, 2025

Lipocine stock maintains Buy rating at H.C. Wainwright on PPD treatment potential - Investing.com Australia

Jul 11, 2025
pulisher
Jun 30, 2025

Lipocine stock maintains Buy rating at H.C. Wainwright as Phase 3 trial begins - Investing.com

Jun 30, 2025
pulisher
Jun 27, 2025

First Patient Receives Lipocene's LPCN 1154 for Postpartum Depression in Phase 3 Clinical Trial - Patient Care Online

Jun 27, 2025
pulisher
Jun 26, 2025

LPCN Begins Pivotal Phase 3 Trial for Postpartum Depression Treatment | LPCN Stock News - GuruFocus

Jun 26, 2025
pulisher
Jun 26, 2025

Lipocine Begins Phase 3 Trial for LPCN 1154 - TipRanks

Jun 26, 2025
pulisher
Jun 23, 2025

Lipocine to Host R&D Event on July 9 - TipRanks

Jun 23, 2025
pulisher
Jun 23, 2025

Lipocine to Host Virtual R&D Investor Event to Discuss LPCN 1154 (BRLIZIO™) as a Treatment for Postpartum Depression on July 9, 2025 - Yahoo Finance

Jun 23, 2025
pulisher
Jun 12, 2025

HC Wainwright Estimates Lipocine’s Q1 Earnings (NASDAQ:LPCN) - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

Lipocine (NASDAQ:LPCN) Given Buy Rating at HC Wainwright - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

LPCN Stock Maintains 'Buy' Rating with $8.00 Price Target | LPCN Stock News - GuruFocus

Jun 10, 2025
pulisher
Jun 09, 2025

Lipocine partner files for Canadian approval of oral TRT drug By Investing.com - Investing.com South Africa

Jun 09, 2025
pulisher
Jun 09, 2025

Verity Pharma Files TLANDO Drug Submission In Canada For Lipocine - Nasdaq

Jun 09, 2025
pulisher
Jun 09, 2025

LPCN: Lipocine's TRT Submission in Canada Marks Key Milestone | - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Lipocine Announces Filing Of New Drug Submission For TLANDO In Canada - MarketScreener

Jun 09, 2025
pulisher
Jun 09, 2025

Lipocine Announces Filing of New Drug Submission for TLANDO® in Canada - PR Newswire

Jun 09, 2025
pulisher
Jun 09, 2025

Lipocine’s Partner Files New Drug Submission in Canada - TipRanks

Jun 09, 2025
pulisher
Jun 09, 2025

Lipocine Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits - Quantisnow

Jun 09, 2025
pulisher
Jun 09, 2025

Groundbreaking Oral Testosterone Treatment Eyes 700,000-Strong Canadian Market After FDA Success - Stock Titan

Jun 09, 2025
pulisher
Jun 06, 2025

Lipocine Inc. (NASDAQ:LPCN) Short Interest Update - Defense World

Jun 06, 2025
pulisher
Jun 04, 2025

Lipocine Approves Key Proposals at Shareholder Meeting - TipRanks

Jun 04, 2025
pulisher
Jun 02, 2025

Q2 Earnings Forecast for Lipocine Issued By HC Wainwright - Defense World

Jun 02, 2025
pulisher
May 30, 2025

HC Wainwright Upgrades Lipocine (NASDAQ:LPCN) to Strong-Buy - Defense World

May 30, 2025
$22.89
price up icon 5.02%
$35.95
price down icon 0.40%
$102.86
price down icon 0.07%
$27.68
price up icon 4.45%
$113.60
price up icon 1.92%
biotechnology ONC
$295.35
price down icon 0.08%
Kapitalisierung:     |  Volumen (24h):